Representations

Canonical SMILES: C[C@]12CCC(=O)C=C1NCC1C2CC[C@@]2(C)C1CC[C@@H]2C(=O)NC(c1ccc(Cl)cc1)c1ccc(Cl)cc1

Standard InChI: InChI=1S/C32H36Cl2N2O2/c1-31-16-14-26-24(18-35-28-17-23(37)13-15-32(26,28)2)25(31)11-12-27(31)30(38)36-29(19-3-7-21(33)8-4-19)20-5-9-22(34)10-6-20/h3-10,17,24-27,29,35H,11-16,18H2,1-2H3,(H,36,38)/t24?,25?,26?,27-,31+,32-/m1/s1

Standard InChI Key: IQDPQNZYVDAQDB-XXRHFDIKSA-N

Associated Targets(Human)

Steroid 5-alpha-reductase 1 755 Activities

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Steroid 5-alpha-reductase 2 937 Activities

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

3-beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type I 15 Activities

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Associated Targets(non-human)

Rattus norvegicus 775804 Activities

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Canis familiaris 36305 Activities

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Molecule Features

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Small molecule	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Drug Indications

MESH ID	MESH Heading	EFO IDs	EFO Terms	Max Phase for Indication	References

Mechanisms of Action

Mechanism of Action	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	References

Properties

Molecular Weight: 551.56	Molecular Weight (Monoisotopic): 550.2154	AlogP: 7.11	#Rotatable Bonds: 4
Polar Surface Area: 58.20	Molecular Species: NEUTRAL	HBA: 3	HBD: 2
#RO5 Violations: 2	HBA (Lipinski): 4	HBD (Lipinski): 2	#RO5 Violations (Lipinski): 2
CX Acidic pKa: 12.90	CX Basic pKa:	CX LogP: 6.46	CX LogD: 6.46
Aromatic Rings: 2	Heavy Atoms: 38	QED Weighted: 0.43	Np Likeness Score: 0.58

References

1. Kenny B, Ballard S, Blagg J, Fox D.. (1997) Pharmacological options in the treatment of benign prostatic hyperplasia., 40 (9): [PMID:9135028] [10.1021/jm960697s]
2. Frye SV, Haffner CD, Maloney PR, Mook RA, Dorsey GF, Hiner RN, Cribbs CM, Wheeler TN, Ray JA, Andrews RC.. (1994) 6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase., 37 (15): [PMID:8057283] [10.1021/jm00041a014]
3. Frye SV, Haffner CD, Maloney PR, Mook RA, Dorsey GF, Hiner RN, Batchelor KW, Bramson HN, Stuart JD, Schweiker SL.. (1993) 6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductase., 36 (26): [PMID:8277514] [10.1021/jm00078a022]

Source

Source(1):

Scientific Literature